Literature DB >> 24685990

Does consistent piperacillin dosing result in consistent therapeutic concentrations in critically ill patients? A longitudinal study over an entire antibiotic course.

Mieke Carlier1, Sofie Carrette2, Veronique Stove3, Alain G Verstraete4, Jan J De Waele2.   

Abstract

Piperacillin plasma concentrations are known to vary between critically ill patients. However, there are no comprehensive data on the variability of antibiotic concentrations within the same patient. The purpose of this study was to investigate the adequacy of dosing during an entire 7-day antibiotic course and to investigate the variability in antibiotic trough concentrations both between patients and within the same patient. Piperacillin trough concentrations were measured daily in critically ill patients with normal renal function. The drug assay was performed using UPLC-MS/MS. The pharmacokinetic/pharmacodynamic target was 100% fT>MIC of the Pseudomonas aeruginosa EUCAST breakpoint. Within- and between-patient variability were calculated as percent coefficient of variation (CV). Eleven patients treated for pneumonia were included in this nested prospective observational cohort study. The median (range) age was 67 (18-79) years, weight was 75 (57-90)kg and BMI was 23.5 (22.3-26.4). The median (range) creatinine clearance on Day 1 of antibiotic treatment was 102 (62-154)mL/min. Trough concentrations were variable, ranging from 4.9 mg/L to 98.0 mg/L. A median CV of 40% for within-patient variability and 57% for between-patient variability was found. Within-patient variability was inversely correlated with SOFA score (R = 0.65, P = 0.027) and APACHE II score on admission (R = 0.73, P = 0.009). In conclusion, piperacillin concentrations varied widely both between patients and within the same patient. Within-patient variability was inversely correlated with disease severity. Consistent dosing of piperacillin/tazobactam does not result in consistent piperacillin concentrations throughout the entire treatment period.
Copyright © 2014 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Biological variation; ICU; PK/PD; TDM; β-Lactams

Mesh:

Substances:

Year:  2014        PMID: 24685990     DOI: 10.1016/j.ijantimicag.2014.01.028

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  11 in total

1.  Antibiotic adjuvants: diverse strategies for controlling drug-resistant pathogens.

Authors:  Erin E Gill; Octavio L Franco; Robert E W Hancock
Journal:  Chem Biol Drug Des       Date:  2015-01       Impact factor: 2.817

2.  Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Authors:  Rajbharan Yadav; Kate E Rogers; Phillip J Bergen; Jürgen B Bulitta; Carl M J Kirkpatrick; Steven C Wallis; David L Paterson; Roger L Nation; Jeffrey Lipman; Jason A Roberts; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

3.  High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.

Authors:  H Woksepp; A Hällgren; S Borgström; F Kullberg; A Wimmerstedt; A Oscarsson; P Nordlund; M-L Lindholm; J Bonnedahl; L Brudin; B Carlsson; T Schön
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-04       Impact factor: 3.267

4.  Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.

Authors:  Ashlan J Kunz Coyne; Mohammad Alshaer; Anthony M Casapao; Veena Venugopalan; Carmen Isache; Jason Ferreira; Christopher A Jankowski
Journal:  Antimicrob Agents Chemother       Date:  2022-09-08       Impact factor: 5.938

5.  Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?

Authors:  Kristina Öbrink-Hansen; Rasmus Vestergaard Juul; Merete Storgaard; Marianne Kragh Thomsen; Tore Forsingdal Hardlei; Birgitte Brock; Mads Kreilgaard; Jakob Gjedsted
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

6.  Provider perspectives on beta-lactam therapeutic drug monitoring programs in the critically ill: a protocol for a multicenter mixed-methods study.

Authors:  Erin F Barreto; Andrew D Rule; Mohammad H Alshaer; Jason A Roberts; Mohd Hafiz Abdul Aziz; Marc H Scheetz; Kristin C Mara; Paul J Jannetto; Ognjen Gajic; John C O'Horo; Kasey R Boehmer
Journal:  Implement Sci Commun       Date:  2021-03-24

Review 7.  Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?

Authors:  Erin F Barreto; Andrew J Webb; Gwendolyn M Pais; Andrew D Rule; Paul J Jannetto; Marc H Scheetz
Journal:  Crit Care Explor       Date:  2021-06-11

8.  We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?

Authors:  Menino Osbert Cotta; Jason A Roberts; Jeffrey Lipman
Journal:  Crit Care       Date:  2016-06-06       Impact factor: 9.097

9.  Piperacillin concentration in relation to therapeutic range in critically ill patients--a prospective observational study.

Authors:  Johannes Zander; Gundula Döbbeler; Dorothea Nagel; Barbara Maier; Christina Scharf; Mikayil Huseyn-Zada; Jette Jung; Lorenz Frey; Michael Vogeser; Michael Zoller
Journal:  Crit Care       Date:  2016-04-04       Impact factor: 9.097

Review 10.  Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.

Authors:  Rui Pedro Veiga; José-Artur Paiva
Journal:  Crit Care       Date:  2018-09-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.